# GMMG-HD6 (NCT02495922)

> A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02495922
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: University of Heidelberg Medical Center
- Conditions: Multiple Myeloma
- Interventions: elotuzumab; Lenalidomide; Bortezomib; Dexamethasone
- Enrollment: 564
- Primary outcome: the best of four treatment strategies regarding Progression Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 17
- YouTube: 1
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=gmmg-hd6-nct02495922

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02495922", "email": "<work email>"}; the inbox owner confirms by the emailed link.